State of Alaska Department of Revenue grew its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 40,103 shares of the biopharmaceutical company’s stock after acquiring an additional 863 shares during the period. State of Alaska Department of Revenue’s holdings in Alexion Pharmaceuticals were worth $5,573,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ALXN. Financial Gravity Wealth Inc. purchased a new position in shares of Alexion Pharmaceuticals during the 1st quarter worth approximately $211,000. Dimensional Fund Advisors LP boosted its position in shares of Alexion Pharmaceuticals by 3.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 384,441 shares of the biopharmaceutical company’s stock worth $42,850,000 after purchasing an additional 12,402 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Alexion Pharmaceuticals by 25.5% in the 1st quarter. Russell Investments Group Ltd. now owns 36,830 shares of the biopharmaceutical company’s stock worth $4,082,000 after purchasing an additional 7,476 shares in the last quarter. Baird Financial Group Inc. boosted its position in shares of Alexion Pharmaceuticals by 11.7% in the 1st quarter. Baird Financial Group Inc. now owns 29,118 shares of the biopharmaceutical company’s stock worth $3,245,000 after purchasing an additional 3,056 shares in the last quarter. Finally, LPL Financial LLC boosted its position in shares of Alexion Pharmaceuticals by 23.4% in the 1st quarter. LPL Financial LLC now owns 27,709 shares of the biopharmaceutical company’s stock worth $3,088,000 after purchasing an additional 5,260 shares in the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.

A number of brokerages have recently commented on ALXN. ValuEngine raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 12th. BidaskClub cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Evercore ISI reissued an “outperform” rating and issued a $158.00 price target on shares of Alexion Pharmaceuticals in a research report on Thursday, July 26th. Jefferies Financial Group reissued a “hold” rating and issued a $123.00 price target on shares of Alexion Pharmaceuticals in a research report on Friday, July 27th. Finally, Stifel Nicolaus cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the stock from $154.00 to $130.00 in a research report on Tuesday, August 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $160.74.

ALXN stock opened at $121.94 on Friday. The company has a market capitalization of $30.98 billion, a P/E ratio of 23.63, a price-to-earnings-growth ratio of 1.27 and a beta of 0.79. Alexion Pharmaceuticals, Inc. has a 12-month low of $102.10 and a 12-month high of $144.91. The company has a current ratio of 2.72, a quick ratio of 2.27 and a debt-to-equity ratio of 0.33.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.58. The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $976.81 million. Alexion Pharmaceuticals had a positive return on equity of 15.21% and a negative net margin of 2.68%. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.56 EPS. As a group, analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.45 EPS for the current year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Read More: Bond

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.